ArticlemedRxiv : the preprint server for health sciences2025
Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe effect of deep brain stimulation (DBS) on gait in patients with Parkinson's disease (PD) is variable but prospective, long-term studies-especially including globus pallidus interna (GPi) stimulation-remain sparse. We tested the hypothesis that subthalamic nucleus (STN) and GPi DBS exert acute and chronic effects on gait in patients with PD.
methodsGait kinematics were collected prospectively on patients with PD with bilateral or unilateral STN or GPi DBS, at baseline before initial DBS activation (n=104), acutely after activation (n=102), and chronically at 1-month (n=75) and 12-months (n=82). Gait speed was the main outcome measure. Kinematic measures of pace, rhythm, and variability and clinical scales were secondary outcome measures.
resultsThe average gait speed at baseline in levodopa off state was abnormally slow (80.6 cm/s). DBS activation acutely increased gait speed (97.4 cm/s, p < 0.001) which was maintained at 1- (93.0 cm/s, p < 0.001) and 12-month follow up (91.2 cm/s, p < 0.001). Acute changes during initial programming predicted chronic gait outcomes. When DBS targets were analyzed separately, only patients receiving bilateral STN or GPi DBS improved gait speed along with kinematic measures of pace, rhythm, and variability. Preoperative levodopa response of the MDS-UPDRS axial sub-score correlated with gait speed response to DBS while the total score did not. DISCUSSION: Patients who received either bilateral STN or GPi DBS improved gait kinematic in levodopa off state at 1 year so both targets may be considered for treatment of gait dysfunction, unlike unilateral implantations which resulted in no change. Acute effects of STN or GPi DBS on gait speed should be considered when programming patients as they predict chronic outcomes. When determining DBS candidacy, the degree of axial symptom improvement with levodopa should be considered.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.